These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16548775)

  • 1. Development of novel therapeutic strategies that target HIF-1.
    Semenza GL
    Expert Opin Ther Targets; 2006 Apr; 10(2):267-80. PubMed ID: 16548775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of hypoxia-inducible factor-1alpha as a cancer therapy target.
    Patiar S; Harris AL
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S61-75. PubMed ID: 17259560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current insights and future perspectives of hypoxia-inducible factor-targeted therapy in cancer.
    Ajith TA
    J Basic Clin Physiol Pharmacol; 2018 Dec; 30(1):11-18. PubMed ID: 30260792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-inducible factor-1 as a therapeutic target in cancer.
    Tang CM; Yu J
    J Gastroenterol Hepatol; 2013 Mar; 28(3):401-5. PubMed ID: 23173651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kamebakaurin inhibits the expression of hypoxia-inducible factor-1α and its target genes to confer antitumor activity.
    Wang KS; Ma J; Mi C; Li J; Lee JJ; Jin X
    Oncol Rep; 2016 Apr; 35(4):2045-52. PubMed ID: 26781327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the hypoxia-inducible factor (HIF) pathway in cancer.
    Poon E; Harris AL; Ashcroft M
    Expert Rev Mol Med; 2009 Aug; 11():e26. PubMed ID: 19709449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of P3971 an orally efficacious novel anticancer agent targeting HIF-1α and STAT3 pathways.
    Godse P; Kumar P; Yewalkar N; Deore V; Lohar M; Mundada R; Padgaonkar A; Manohar S; Joshi A; Bhatia D; Desai N; Damre A; Bhonde M; Joshi K; Sharma R; Kumar S
    Anticancer Agents Med Chem; 2013 Nov; 13(9):1460-6. PubMed ID: 24102269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical biology approach for the development of hypoxia inducible factor (HIF) inhibitor LW6 as a potential anticancer agent.
    Naik R; Han S; Lee K
    Arch Pharm Res; 2015 Sep; 38(9):1563-74. PubMed ID: 26310207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.
    Rohwer N; Cramer T
    Drug Resist Updat; 2011 Jun; 14(3):191-201. PubMed ID: 21466972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecules targeting HIF-1α pathway for cancer therapy in recent years.
    Tang W; Zhao G
    Bioorg Med Chem; 2020 Jan; 28(2):115235. PubMed ID: 31843464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia inducible factor in hepatocellular carcinoma: A therapeutic target.
    Lin D; Wu J
    World J Gastroenterol; 2015 Nov; 21(42):12171-8. PubMed ID: 26576101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinases as upstream regulators of the HIF system: their emerging potential as anti-cancer drug targets.
    Dimova EY; Michiels C; Kietzmann T
    Curr Pharm Des; 2009; 15(33):3867-77. PubMed ID: 19671044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dictamnine promotes apoptosis and inhibits epithelial-mesenchymal transition, migration, invasion and proliferation by downregulating the HIF-1α and Slug signaling pathways.
    Wang JY; Wang Z; Li MY; Zhang Z; Mi C; Zuo HX; Xing Y; Wu YL; Lian LH; Xu GH; Piao LX; Ma J; Jin X
    Chem Biol Interact; 2018 Dec; 296():134-144. PubMed ID: 30266538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibiting the hypoxia response for cancer therapy: the new kid on the block.
    Koh MY; Spivak-Kroizman TR; Powis G
    Clin Cancer Res; 2009 Oct; 15(19):5945-6. PubMed ID: 19789327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells.
    Manohar SM; Padgaonkar AA; Jalota-Badhwar A; Rao SV; Joshi KS
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):15-27. PubMed ID: 22083267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cucurbitacin B inhibits the translational expression of hypoxia-inducible factor-1α.
    Ma J; Zi Jiang Y; Shi H; Mi C; Li J; Xing Nan J; Wu X; Joon Lee J; Jin X
    Eur J Pharmacol; 2014 Jan; 723():46-54. PubMed ID: 24333213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular redox status regulates hypoxia inducible factor-1 activity. Role in tumour development.
    Martínez-Sánchez G; Giuliani A
    J Exp Clin Cancer Res; 2007 Mar; 26(1):39-50. PubMed ID: 17550131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor.
    Lee K; Kim HM
    Arch Pharm Res; 2011 Oct; 34(10):1583-5. PubMed ID: 22076756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy.
    Yu T; Tang B; Sun X
    Yonsei Med J; 2017 May; 58(3):489-496. PubMed ID: 28332352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).
    Ban HS; Uto Y; Won M; Nakamura H
    Expert Opin Ther Pat; 2016; 26(3):309-22. PubMed ID: 26882240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.